Researchers have shown that the loss of a protein called AMBRA1 can cause tumors to form in mice and is linked with worse outcomes in some human tumors. A lack of AMBRA1 may make some tumors resistant to CDK4/6 inhibitor drugs. The new research may lead to strategies for re-sensitizing cancer cells to these drugs.

In a clinical trial for children with advanced Hodgkin lymphoma, a treatment regimen using brentuximab vedotin (Adcetris) instead of the chemotherapy drug vincristine allowed 35% of participants to avoid radiation therapy. Minimizing radiation spares these children from long-term health problems that can come with it.

The results of a large clinical trial show that the investigational immunotherapy tebentafusp, a bispecific fusion protein, improves overall survival in patients with metastatic uveal melanoma. There is no standard treatment for the disease and, once it has spread, many patients do not survive for a year.

In a large clinical trial, cancer survivors treated with one of two types of acupuncture reported modest improvements in pain compared with those who received standard pain treatments. The study included the ear acupuncture called battlefield acupuncture, and enrolled survivors of many different cancer types.